For investors, the question behind the Indira IVF Sabine acquisition is simple: what does a reported ₹1,200 crore to ₹1,300 crore deal for a Kerala hospital tell us about a fertility chain that is preparing to list? Reports on 28 October 2026 say Indira IVF is in advanced talks to take a 70% to 75% stake in Sabine Hospital and Research Centre. The talks are unconfirmed, and this article sets out what is known, what is not and why the answers matter.
Key takeaways from the Indira IVF Sabine acquisition for investors
- Reported value: ₹1,200 crore to ₹1,300 crore for a 70% to 75% majority stake.
- Reported seller: CX Partners, said to have invested in Sabine only last year; O3 Capital is reported to be facilitating.
- Indira IVF is reported to be planning a listing aimed at raising about ₹3,500 crore and is backed by EQT.
- Sabine’s revenue, profit and debt have not been disclosed, so no valuation multiple can be calculated.
- Valuation, due diligence and regulatory approvals are reported as the remaining steps.
The reported terms of the Indira IVF Sabine acquisition
The reports, which name no sources and quote no executives, put the price at up to ₹1,300 crore and the stake at 70% to 75%. By our own arithmetic, that implies a valuation of roughly ₹1,600 crore to ₹1,860 crore for 100% of Sabine if the whole range is taken at face value: ₹1,200 crore divided by 0.75 is ₹1,600 crore, and ₹1,300 crore divided by 0.70 is about ₹1,857 crore. That is our calculation and not a reported figure, and it assumes the deal value refers only to the stake being bought. Company information is at indiraivf.com.
What Sabine brings to the Indira IVF Sabine acquisition
Sabine was founded in 2010 and is reported to run two Kerala facilities with about 300 beds, specialising in fertility, maternity and newborn care. It is credited with more than 6,000 IVF cycles a year, which we could not verify. For a chain, the attraction is a hospital platform with obstetric and neonatal capacity, not only a fertility clinic. The reports also say the deal would give Indira IVF an entry into Kerala.
The IPO angle
Indira IVF’s planned listing has been reported since 2025, with draft papers filed confidentially. Securities rules and disclosure are overseen by SEBI. Buying a hospital ahead of a listing can increase reported revenue and geographic reach, but it can also add debt, integration risk and a fresh set of numbers to explain in a prospectus. The reports link the deal to faster national scaling ahead of the listing; we have no company statement confirming that.
Seller economics in the Indira IVF Sabine acquisition
If CX Partners invested only last year, as reported, an exit now would be a short holding period. We do not know the price it paid, so we cannot calculate a return, and we do not speculate. The reported facilitation by an advisory firm is a normal feature of private deals.
Questions investors should ask about the Indira IVF Sabine acquisition
Several practical questions would help judge the deal if it is announced. How is it funded: from cash, new debt or fresh capital? What did Sabine earn, and how fast has it grown? How dependent is it on a few senior doctors? What share of its revenue comes from IVF as opposed to maternity and neonatal care, which have different margins? Will the founder stay involved? The reports answer none of these, and we do not guess.
Timeline of the Indira IVF Sabine acquisition
- 2010: Sabine is founded.
- Last year: CX Partners reportedly invests in Sabine.
- 2025 to 2026: Indira IVF is reported to buy centres in Kolkata, Puducherry and Gujarat.
- 28 October 2026: reports of advanced talks emerge.
Market data behind the Indira IVF Sabine acquisition
Acumen Research and Consulting’s report In-Vitro Fertilization Market Size, Share, Analysis, Trends and Forecast 2024 to 2032 values the global in-vitro fertilisation market at USD 25.57 billion in 2023 and projects USD 44.28 billion by 2032, a CAGR of 6.4% from 2024 to 2032. It puts Asia Pacific as the fastest-growing region at more than 7.2% a year and says fertility clinics held around 80% of the market in 2023. The report’s updated date predates its base year and the figures are global, so they are context and not a valuation benchmark. See our industry insights.
General background: how fertility chains create value
Fertility chains earn money per treatment cycle and benefit from scale in embryology labs, brand marketing and doctor recruitment. Growth comes from opening new centres or acquiring existing ones. Clinical outcomes, such as live-birth rates, are central to reputation, so investors usually look for evidence that acquired centres keep quality after a takeover.
Our analysis of the Indira IVF Sabine acquisition
In our assessment, the Indira IVF Sabine acquisition would be a sizeable bet on a single state and on the hospital model, and its significance for investors depends on information that is not public: Sabine’s earnings, how the deal would be funded and how it would sit in the listing documents. A reported majority stake suggests control, which would let Indira IVF consolidate Sabine’s results. We do not give investment advice or predict valuation.
What is not disclosed about the Indira IVF Sabine acquisition
- Official confirmation and the final terms.
- Sabine’s financials.
- Funding sources for the purchase.
- Regulatory approvals required and their timing.
Risks and caveats
These are reports of talks that may not conclude. Prices and stakes can change. Our valuation arithmetic is illustrative. This article is news reporting and not investment advice.
What to watch next
- A formal announcement or exchange filing.
- Indira IVF’s listing timetable.
- Disclosure of Sabine’s results.
- Rival fertility chains’ deals.
FAQ
Is the Indira IVF Sabine acquisition confirmed?
No. It is reported as being in talks.
What valuation does it imply?
By our rough calculation, about ₹1,600 crore to ₹1,860 crore for all of Sabine, if the reported figures are taken at face value.
Is Indira IVF listed?
Not in the material we reviewed; a listing is reported as planned.
How we reported this: we relied on press reports of the talks, company and regulator sites and the Acumen Research and Consulting report cited above, and attributed every claim. Our own calculations are labelled. Last updated 28 October 2026. This is news reporting and not advice.
